| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6310f9872a650e799a0648f35bab1a59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bf6318336363a736bfed71987f7ebc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1970ec4afee53e4eb06f118a5398bc05 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2019-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01968d8632f9e4796e38e0da4954e03c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0305ce200bc9953cfa9d44b9026134dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b98cca1ab48f882c4f381791fad7ab24 |
| publicationDate |
2019-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019246142-A1 |
| titleOfInvention |
Soluble bispecific fusion proteins for cancer immunotherapy |
| abstract |
A bispecific fusion protein agent may include at least one binding site with human IgG1 hinge that specifically binds to a function protein and at least another one binding site with human IgG1 hinge that specifically binds to a different function protein. For example, the bispecific fusion protein agent can be a bispecific fusion protein agent PD-1/LAG-3 that includes a biding site of the human IgGl hinge that specifically crosslinks to a LAG-3 molecule, and another binding site of the human IgG1 hinge that specifically crosslinks to a PD-1 molecule. |
| priorityDate |
2018-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |